Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 15/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.43 |
| ▸ | FAP | Q12884 | 3/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981952 | 0.85 | DPP4 (0.44) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL16730160 | 0.82 | HRH3 (0.56) | CYP2D6KCNH2HRH3DPP4EPHX2 | |
| SCHEMBL10201881 | 0.82 | CYP2D6 (0.59) | CYP2D6KCNH2HRH3EPHX2MEN1 | |
| SCHEMBL19981943 | 0.80 | ALDH1A1 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL17787623 | 0.80 | ALDH1A1 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL22630456 | 0.80 | ALDH1A1 (0.61) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL29326408 | 0.80 | DPP4 (0.40) | CYP2D6KCNH2HRH3DPP4DPP7 | |
| SCHEMBL25676126 | 0.79 | HRH3 (0.56) | CYP2D6KCNH2HRH3DPP4DPP8 | |
| SCHEMBL14147669 | 0.79 | DPP4 (0.49) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL4693217 | 0.77 | DPP4 (0.46) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | CYP2D6 81/4885KCNH2 3495/4885HRH3 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.